文献速递耳科与耳神经

烟酰胺腺嘌呤二核苷酸(NAD+)促进突发性感音神经性聋听力恢复:随机对照试验

NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial.
PubMed 文献 · Laryngoscope · 2025-10-01

该随机双盲对照试验于2022年6月至2024年6月纳入38例突发性感音神经性聋患者,随机分为NAD+联合标准治疗组(n=18)与标准治疗对照组(n=20)。NAD+组听力改善(40.21 dB HL)显著优于对照组(23.06 dB HL,t=2.722,p=0.010),有效率更高(94.44% vs 60.00%,Z=-3.014,p=0.003),恢复时间更短(62.97 vs 175.98天,p=0.028),耳鸣和耳闷改善也更明显。

要点

  • NAD+联合标准治疗组听力改善40.21 dB HL,显著优于标准治疗对照组的23.06 dB HL(p=0.010)。
  • NAD+组有效率94.44%,高于对照组的60.00%(Z=-3.014,p=0.003)。
  • NAD+组恢复时间62.97天,短于对照组的175.98天(p=0.028),耳鸣和耳闷改善更明显。

核心结论

  • NAD+在改善突发性感音神经性聋患者听力和缩短恢复时间方面更有效,并有助于耳鸣和耳闷的管理。

研究设计与样本

  • 随机双盲对照临床试验,于2022年6月至2024年6月开展,共纳入38例突发性感音神经性聋患者。
  • NAD+组(NAD+联合标准治疗,n=18)与对照组(标准治疗,n=20)随机分组。
  • 主要结局为纯音听阈(PTA)改善、基于Siegel标准计算的恢复率及平均恢复时间,从基线评估至3个月随访。

主要发现

  • NAD+组听力改善40.21 dB HL,对照组为23.06 dB HL(t=2.722,p=0.010)。
  • NAD+组有效率94.44%,对照组为60.00%(Z=-3.014,p=0.003)。
  • NAD+组恢复时间62.97天,对照组为175.98天(p=0.028)。
  • NAD+组在治疗后7天至3个月出现显著的组×时间交互效应(F=2.867,p=0.030),改善幅度更大。
  • 耳鸣和耳闷在NAD+组改善更明显,尤其在3个月后;治疗前耳鸣和耳闷评分较高与NAD+治疗突发性感音神经性聋的更好结局相关。

关键数值与推荐

  • NAD+组听力改善40.21 dB HL vs 对照组23.06 dB HL(t=2.722,p=0.010)。
  • NAD+组有效率94.44% vs 对照组60.00%(Z=-3.014,p=0.003)。
  • NAD+组恢复时间62.97天 vs 对照组175.98天(p=0.028)。
  • 组×时间交互效应:F=2.867,p=0.030。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group. METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups. RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.030), with greater improvements from 7 days to 3 months post-treatment. Recovery time was shorter in the NAD+ group (62.97 vs. 175.98 days, p = 0.028). Tinnitus and aural fullness improved more in the NAD+ group, especially after 3 months. Higher pre-treatment tinnitus and aural fullness scores were linked to better outcomes with NAD+ for SSNHL. CONCLUSIONS: NAD+ was more effective in improving hearing and reducing recovery time in SSNHL patients and also benefited tinnitus and aural fullness management.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Gao M, Guan Y, Yue X, et al. NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial. Laryngoscope. 2025. PMID: 41035311. doi:10.1002/lary.70173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。